DIABETES

Dapagliflozin DECLAREd safe

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

    Original article

    1. Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1812389 (2018)

    Further reading

    1. Nassif, M. & Kosiborod, M. Effect of glucose-lowering therapies on heart failure. Nat. Rev. Cardiol. 15, 282–291 (2018)

    Download references

    Author information

    Correspondence to Gregory B. Lim.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Further reading